Argonaute RNA Ltd. is developing safe and reliable methods of temporarily silencing target genes in different tissue cells without the need for chemical modification. This represents a radically different approach from the current orthodoxy.
Currently, all siRNA drugs globally are chemically modified to ensure their delivery into cells. This makes siRNA drugs expensive and time-consuming to produce - and potentially toxic in chronic use.
Argonaute RNA is using its novel technology platform to pursue a number of therapeutic opportunities, with an initial focus on cardiovascular disease.
Our CEO is a leading cardiovascular/metabolic clinician but also has extensive prior commercial experience - he was the CMO and a board director at one of the world's leading siRNA companies.